Key result
Longer door-to-balloon minus door-to-needle times were associated with increased in-hospital mortality, reducing the survival advantage of primary PCI over fibrinolysis.
Why the study?
Does increased door-to-balloon minus door-to-needle time reduce the survival advantage of primary PCI over fibrinolysis in patients with STEMI?
Observational (n=192,509)
Yes
Does increased door-to-balloon minus door-to-needle time reduce the survival advantage of primary PCI over fibrinolysis in patients with STEMI?
The mortality advantage of primary PCI over fibrinolysis in STEMI is attenuated by treatment delays, emphasizing the need to consider both hospital PCI delays and patient characteristics when selecting a reperfusion strategy.
Answers are grounded in this paper and cite their sources.
Supports delay-adjusted STEMI reperfusion decisions; hypothesis-generating and requires randomized confirmation before practice change.
BACKGROUND: It has been suggested that the survival benefit associated with primary percutaneous coronary intervention (PPCI) in ST-segment elevation myocardial infarction may be attenuated if door-to-balloon (DB) time is delayed by >1 hour beyond door-to-needle (DN) times for fibrinolytic therapy. Whereas DB times are rapid in randomized trials, they are often prolonged in routine practice. We hypothesized that in clinical practice, longer DB-DN times would be associated with higher mortality rates and reduced PPCI survival advantage. We also hypothesized that in addition to PPCI delays, patient risk factors would significantly modulate the relative survival advantage of PPCI over fibrinolysis. METHODS AND RESULTS: DB-DN times were calculated by subtracting median DN time from median DB time at a hospital using data from 192,509 patients at 645 National Registry of Myocardial Infarction hospitals. Hierarchical models that adjusted simultaneously for both patient-level risk factors and hospital-level covariates were used to evaluate the relationship between PCI-related delay, patient risk factors, and in-hospital mortality. Longer DB-DN times were associated with increased mortality (P<0.0001). The DB-DN time at which mortality rates with PPCI were no better than that of fibrinolysis varied considerably depending on patient age, symptom duration, and infarct location. CONCLUSIONS: As DB-DN times increase, the mortality advantage of PPCI over fibrinolysis declines, and this advantage varies considerably depending on patient characteristics. As indicated in the American College of Cardiology/American Heart Association guidelines, both the hospital-based PPCI-related delay (DB-DN time) and patient characteristics should be considered when a reperfusion strategy is selected.
No takes yet. Share an insight, caveat, or question.
Pinto et al. (2006) conducted an observational in ST-segment elevation myocardial infarction (n=192,509). Longer door-to-balloon minus door-to-needle (DB-DN) times vs. Shorter DB-DN times / Fibrinolysis was evaluated on In-hospital mortality (p=<0.0001). Longer door-to-balloon minus door-to-needle times were associated with increased in-hospital mortality, reducing the survival advantage of primary PCI over fibrinolysis.
Synapse has enriched 10 related papers. Consider them for comparative context: